How Adequate is the Adequate Kidney Function for Clinical Trial Enrollment of Novel Anticancer Drugs?

How Adequate is the Adequate Kidney Function for Clinical Trial Enrollment of Novel Anticancer Drugs?

Excessively restrictive eligibility criteria hinder the enrollment of cancer patients to clinical trials. Those patients are supposed to represent the range of characteristics of the overall population with particular cancer. This, in turn, affects the generalizability of results and efficiency of t...

Full description

Bibliographic Details
Main Authors:	Nehal Gamal, Kyrillus S. Shohdy
Format:	Article
Language:	English
Published:	Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine 2020-12-01
Series:	Research in Oncology
Subjects:	abemaciclib clinical trials eligibility criteria kidney function tucatinib
Online Access:	https://resoncol.journals.ekb.eg/article_104142_860510327b2a79921e3af298b4f05ca5.pdf

Similar Items

Time to broaden the eligibility criteria in paediatric oncology trials? An analysis of patients with rhabdomyosarcoma non-eligible to the EpSSG RMS2005 trial
by: Gianni Bisogno, et al.
Published: (2023-01-01)

Investigating potential disparities in clinical trial eligibility and enrollment at an NCI‐designated comprehensive cancer center
by: Monica A. Patel, et al.
Published: (2023-06-01)

Semantic categorization of Chinese eligibility criteria in clinical trials using machine learning methods
by: Hui Zong, et al.
Published: (2021-04-01)

Eligibility criteria in clinical trials in breast cancer: a cohort study
by: Katarzyna Szlezinger, et al.
Published: (2023-07-01)

Adequate enrollment of women in cardiovascular drug trials and the need for sex-specific assessment and reporting
by: Corinne Carland, et al.
Published: (2022-05-01)

Is Irritable Bowel Syndrome Considered as Comorbidity in Clinical Trials of Physical Therapy Interventions in Fibromyalgia? A Scoping Review
by: Paula Mª Rodríguez-Castillejo, et al.
Published: (2021-10-01)

Eligible-and-enrolled vs. eligible-but-not-enrolled patients with chronic ischaemic heart failure in randomized clinical trials of myocardial regeneration
by: Łukasz Czyż, et al.
Published: (2022-11-01)

Feasibility of Using Oncology-Specific Electronic Health Record (EHR) Data to Emulate Clinical Trial Eligibility Criteria
by: Thomas W. Wilson, et al.
Published: (2023-05-01)

Eligibility of real-world patients with metastatic breast cancer for clinical trials
by: Atul Batra, et al.
Published: (2020-12-01)

Striking a match between FHIR‐based patient data and FHIR‐based eligibility criteria
by: Brian S. Alper, et al.
Published: (2023-10-01)

Clinical drug trials in general practice: how well are external validity issues reported?
by: Anja Maria Brænd, et al.
Published: (2017-12-01)

Automated classification of clinical trial eligibility criteria text based on ensemble learning and metric learning
by: Kun Zeng, et al.
Published: (2021-07-01)

More efficient and inclusive time-to-event trials with covariate adjustment: a simulation study
by: Raphaëlle Momal, et al.
Published: (2023-06-01)

A comparative study of pre-trained language models for named entity recognition in clinical trial eligibility criteria from multiple corpora
by: Jianfu Li, et al.
Published: (2022-09-01)

Are trial participants adequately safeguarded by the ethics committees – the Indian scenario?
by: Karan eThakkar, et al.
Published: (2014-06-01)

Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible
by: Brian L. Egleston, et al.
Published: (2018-03-01)

Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer
by: Elizabeth J. Rowe, et al.
Published: (2022-12-01)

HORSE-RACING EFFECT AND CLINICAL TRIALS IN OLDER PERSONS
by: Matteo eCesari, et al.
Published: (2014-07-01)

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations
by: Amelie Boquoi, et al.
Published: (2022-04-01)

Are published randomized clinical trials abstracts on periodontics reported adequately?
by: Fahad Alharbi, et al.
Published: (2020-12-01)

Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren’s syndrome: examination of data from the UK Primary Sjögren’s Syndrome Registry
by: Alexandre Dumusc, et al.
Published: (2018-02-01)

Editorial: Clinical cancer research in vulnerable populations
by: Laura Tack, et al.
Published: (2023-03-01)

Barriers to non-small cell lung cancer trial eligibility
by: Jeffrey J. Hardesty, et al.
Published: (2018-03-01)

Inclusion of premenopausal women in breast cancer clinical trials
by: Kelsey L. Corrigan, et al.
Published: (2022-12-01)

Clinical trial recruiters’ experiences working with trial eligibility criteria: results of an exploratory, cross-sectional, online survey in the UK
by: William J. Cragg, et al.
Published: (2021-10-01)

Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer’s Disease
by: Younghoon Seo, et al.
Published: (2022-02-01)

When should a university student be allowed academic accommodations for attention-deficit/hyperactivity disorder? A position statement for a unified procedure for use in Brazil
by: Bernardo Oppermann Lisboa, et al.
Published: (2023-08-01)

Medical eligibility criteria for using various methods of contraception
by: V N Prilepskaya, et al.
Published: (2014-02-01)

A consensus conference report on defining the eligibility criteria for pediatric palliative care in Italy
by: Momcilo Jankovic, et al.
Published: (2019-07-01)

Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature
by: Axel de Bernardi, et al.
Published: (2024-01-01)

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
by: Ippazio Cosimo Antonazzo, et al.
Published: (2023-02-01)

Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
by: Lauren A. Marcath, et al.
Published: (2021-03-01)

Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria
by: Muneer J. Al-Husseini, et al.
Published: (2019-08-01)

Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
by: Inge M. Werter, et al.
Published: (2022-11-01)

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
by: Peter A. Kaufman, et al.
Published: (2023-10-01)

Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
by: Lauren A. Marcath, et al.
Published: (2018-11-01)

External validity of randomized clinical trial studying preventing depressive symptoms following acute coronary syndrome
by: Michael Tvilling Madsen, et al.
Published: (2021-08-01)

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
by: Zaid Sirhan, et al.
Published: (2022-07-01)

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
by: Qiuji Wu, et al.
Published: (2020-08-01)

Indicators for adequate diabetes care for the indigenous communities of Ecuador
by: Jimmy Martin‐Delgado, et al.
Published: (2022-12-01)